Aesthetic Management Partners Introduces Cellenis® Exo-ME™, Bringing Autologous Extracellular Vesicle Technology to the Skin Booster Market
Aesthetic Management Partners Introduces Cellenis® Exo-ME™, Bringing Autologous Extracellular Vesicle Technology to the Skin Booster Market
PR Newswire
MEMPHIS, Tenn., Oct. 6, 2026
New technology expands the Cellenis® PRP portfolio, building on a globally utilized platform to deliver a personalized approach to skin quality
MEMPHIS, Tenn., Oct. 6, 2026 /PRNewswire/ -- Aesthetic Management Partners today announced the introduction of Cellenis® Exo-ME™, an autologous, point-of-care system that concentrates a patient's own blood-derived components — including extracellular vesicles (EVs) and bioactive proteins — offered as a new option in the growing skin-booster market.
Cellenis® Exo-ME™ extends the Cellenis® PRP portfolio, building on the blood-based technologies used by healthcare professionals worldwide. The system processes a standard blood draw into a concentrated autologous preparation of the patient's own EVs, including exosomes, and bioactive proteins.
As interest in skin quality grows, Exo-ME™ is intended for use within aesthetic skin and scalp protocols, giving practitioners a way to incorporate a patient's own concentrated blood-derived components into individualized care. It is also offered as an option in aesthetic scalp and hair protocols.
"Cellenis® Exo-ME™ is a natural next step in personalized, autologous care. We're building on an established, globally used Cellenis® PRP platform and extending it using the patient's own biology as the starting point," said Erik Dowell, CEO of Aesthetic Management Partners.
Building on the Patient's Own Biology
Extracellular vesicles are naturally occurring, cell-derived particles that are the subject of ongoing scientific study. Cellenis® Exo-ME™ is designed to concentrate the EVs and bioactive proteins already present in the patient's own blood, producing an autologous preparation for use in aesthetic skin and scalp protocols.
The introduction of Exo-ME™ reflects growing interest in personalized, autologous approaches, and gives healthcare professionals a new option for working with a patient's own concentrated blood-derived components, while building on the established Cellenis® PRP platform.
About Aesthetic Management Partners
Aesthetic Management Partners provides innovative technologies, products, clinical education, and business solutions to aesthetic practices. Through its growing portfolio and commitment to practice support, AMP helps providers expand their offerings and elevate the patient experience.
For more information about Exo-ME™ and Aesthetic Management Partners, visit https://aestheticmanagementpartners.com/
Media Contact:
Marina Kamenakis
Vice President, Marketing
Aesthetic Management Partners
Marina.Kamenakis@amplifimd.com
SOURCE Aesthetic Management Partners
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
This 1-Star Stock Trades at a 94% Premium. Is It Time to Sell?
10 Best Blue-Chip Stocks to Buy for the Long Term
United States